Jihenne Ben Aissa-Haj, PhD in Genomics and Oncogenetics, Biomarker Program Manager at mc PHaRMa and AIMS Pharma, shared a post on LinkedIn:
“An incredible experience at the AORTIC 2025 Conference (2–5 November)
It was a true honor for AIMS Pharma and mc Pharma to be represented at AORTIC 2025, where my colleague Selim Sethom and I had the opportunity to showcase our work and engage with inspiring experts from across the continent.
Attending AORTIC was an exceptional opportunity for networking, exchanging ideas, and deepening insights into the evolving landscape of precision medicine in Africa.
Connecting with key stakeholders from oncology, genetics, and the pharmaceutical sector added tremendous value opening new perspectives for collaboration and innovation in cancer care.
I am truly honored to have been selected for an oral communication grant to present our study:
‘A Stepwise Genetic Screening Strategy for Diffuse Gastric Cancer in Tunisia: A Focus on CDH1 and Beyond.’
Grateful for the engaging discussions, shared expertise, and inspiring commitment of all participants working to advance precision oncology in Africa.
The journey continues, I’ll be in Annaba for the 3rd FMC, keeping the momentum alive and continuing to build bridges for precision medicine across our region.
A heartfelt thank you to the AORTIC community for this enriching experience and excellent organization!”
More posts featuring Jihenne Ben Aissa-Haj.
